Bioceltix develops off-the-shelf biopharmaceuticals utilizing mesenchymal stem cells (MSCs) to create effective treatments for common veterinary conditions. The company addresses the high demand for reliable therapeutic solutions in companion animal care by leveraging the immunomodulatory properties of MSCs and their biologically active substances.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GOFounders
Product
Problem
Veterinary medicine faces a need for readily available, consistent, and effective treatments for common conditions in companion animals. Current therapeutic options may lack the reliability and efficacy desired for optimal animal care.
Solution
Bioceltix develops off-the-shelf biopharmaceuticals based on mesenchymal stem cells (MSCs) and their biologically active substances to address prevalent veterinary conditions. By harnessing the immunomodulatory properties of MSCs, Bioceltix creates innovative biological drugs intended to provide reliable therapeutic solutions. These ready-to-use products aim to meet the high demand for effective treatments in the companion animal healthcare market. The company focuses on utilizing both the cells and the substances they produce in industrial bioreactor cultures as active components of their biological drugs.
Target Audience
The primary customers are veterinarians and animal healthcare providers seeking reliable and effective therapeutic solutions for companion animals.
Features
- Utilizes mesenchymal stem cells (MSCs) as the active ingredient in biological drugs
- Leverages biologically active substances produced by MSCs
- Develops off-the-shelf products for immediate use
- Focuses on immunomodulatory properties of MSCs for therapeutic applications
- Targets common conditions in companion animals
- Developing drug candidates for atopic dermatitis in dogs and joint inflammation in horses